Skip to content
The GLP-1 Verdict
Menu

Head-to-head verdict

CoreAge Rx vs Belle Health

Two GLP-1 providers, ruled side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.

WinnerGrade A · #1

CoreAge Rx

The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.

Visit CoreAge Rx
vs
Grade C · #203

Belle Health

Nine-year-old Utah telehealth firm offering compounded and brand GLP-1s in all fifty states, carrying an unresolved February 2026 FDA warning letter.

Visit Belle Health

The verdict

Winner: CoreAge Rx

CoreAge Rx takes it with a higher Verdict Score — 94/100 to 67/100 (grade A vs C). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. Belle Health still earns its place — someone who wants a compounded starting price at the low end of the market with the option to switch to brand Wegovy or Zepbound on the same account.

Factor by factor

Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.

92Real-world results65
97Price honesty60
96Prescriber access75
88Formulary choice85
95Cancellation fairness50
93Member support70

Price, coverage & features

MetricCoreAge RxBelle Health
Verdict Score94/10067/100
GradeAC
Semaglutide$149/moFrom $119/mo (compounded)
Tirzepatide$349/moFrom $175/mo (compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualNoNo

CoreAge Rx

What we like

  • Flat, all-in monthly price with no intro-rate step-ups after month one
  • Both compounded semaglutide and tirzepatide on one account
  • Available in all 50 states
  • Straightforward, low-friction cancellation

The caveats

  • Not the cheapest — flat-price challengers like Trimi Health and Alan Meds undercut its sticker price
  • No FDA-approved brand-name option (compounded only)
  • Does not yet publicly name its 503A/B pharmacy partner

Belle Health

What we like

  • Offers brand Wegovy (from $1,400/mo) and brand Zepbound (from $1,999/mo) alongside the compounded lines, so a switch to an FDA-approved product does not mean changing provider
  • Compounded prices are published before intake: from $119 a month for semaglutide and from $175 a month for tirzepatide
  • Weekly registered-dietitian sessions are included in the monthly price at no extra charge
  • Trading since 2017, which is unusually long for this segment
  • The site states plainly that 'Compounded medications are not evaluated or approved by the FDA' rather than burying the caveat

The caveats

  • FDA Warning Letter 721795, dated 20 February 2026, to Belle Health LLC dba Belle over its website's compounded semaglutide and tirzepatide claims under FDCA sections 502(a) and 502(bb); no closeout letter has been published
  • Compounded semaglutide and tirzepatide are not FDA-approved and are not reviewed by the FDA for safety, effectiveness or quality
  • Both compounded prices are 'from' prices, so the figure you are quoted after intake may be higher than the one advertised
  • The pharmacy partners named in the Terms have been swapped out entirely, and two of the current four have publicly stepped back from GLP-1 compounding
  • No refunds on prescription or compounded products once shipped, and no telephone support is published

Our pick — visit

Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.

Visit CoreAge Rx Read the full CoreAge Rx review →

Also worth a look

Someone who wants a compounded starting price at the low end of the market with the option to switch to brand Wegovy or Zepbound on the same account.

Visit Belle Health Read the full Belle Health review →

Keep comparing

Neither of these has to be the answer: the rivals we rank against CoreAge Rx cover the 7 programmes closest to it, and the same shortlist for Belle Health does the reverse.

Or browse the full comparison hub and the complete rankings.

Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.